Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Galaxy Therapeutics
AddedFeb 18, 2024
UpdatedJun 18, 2026
Galaxy Therapeutics

Galaxy Therapeutics

Angel

Galaxy Therapeutics offers innovative neurovascular devices for effective aneurysm treatment and improved patient care.

HQ
Milpitas, CA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Galaxy Therapeutics is dedicated to revolutionizing brain aneurysm treatment through innovative neurovascular devices. The company's mission is to enhance the rate of curing neurovascular diseases by offering devices that are easy to deploy, provide fluoroscopic visualization, and are effective for both shallow and large aneurysms. This focus aims to improve patient care and treatment outcomes in the neurovascular market.

Galaxy Therapeutics has made significant strides in the medical device industry, particularly in the field of neurovascular health. Their cutting-edge products have gained attention for their potential to transform aneurysm treatment, contributing to better patient outcomes. The company's commitment to innovation and patient care positions it as a key player in the neurovascular device market.

Galaxy Therapeutics - Similar Companies

Neurvana Medical logo

Neurvana Medical

NeuRx Medical logo

NeuRx Medical

neurxmed.com

Nectero Medical logo

Nectero Medical

necteromed.com

NeuroVasc Technologies logo

NeuroVasc Technologies

NeuroVasx logo

NeuroVasx

Evon Medics logo

Evon Medics

Epic Neuro logo

Epic Neuro

Jan Medical logo

Jan Medical

janmedical.com

Clear Mind Medical logo

Clear Mind Medical

Rist Neurovascular logo

Rist Neurovascular

ristneuro.com

BrainHealth logo

BrainHealth

Neuro42 logo

Neuro42

CereVasc logo

CereVasc

cerevasc.com

Galvanize Therapeutics logo

Galvanize Therapeutics

galvanizetx.com

Alcyone Lifesciences logo

Alcyone Lifesciences

Galaxy Therapeutics - Quick Facts

Who are Galaxy Therapeutics' competitors?

Companies similar to Galaxy Therapeutics include Neurvana Medical, NeuRx Medical, Nectero Medical and NeuroVasc Technologies.

When was Galaxy Therapeutics founded?

Galaxy Therapeutics was founded in 2020.

Where is Galaxy Therapeutics' headquarters located?

Galaxy Therapeutics' headquarters is located in Milpitas, CA, US.

When was Galaxy Therapeutics' last funding round?

Galaxy Therapeutics' most recent funding round was for $256k (USD) in April 2021.

How much has Galaxy Therapeutics raised to-date?

As of Apr 23, 2021, Galaxy Therapeutics has raised a total of $256k (USD).

How many employees does Galaxy Therapeutics have?

Galaxy Therapeutics has 7 employees as of Feb 5, 2024.

Galaxy Therapeutics - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Robotics
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified